{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:39:46Z","timestamp":1782275986152,"version":"3.54.5"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Outcomes of allogeneic hematopoietic cell transplantation (HCT) for patients with advanced acute leukemia and myelodysplastic syndromes (MDS) remain uncertain. All published series include the important and often not stated selection bias that influences outcome. Performance status, patient age, prompt donor availability, risk phenotype of the leukemia, and tumor burden all influence the decision-making process about HCT with active disease. In addition, patients with MDS do not achieve a true pre-HCT complete remission, and thus much less stringent measures are used to indicate suitability for allografting in that disease. Post-HCT maintenance or investigational approaches for tumor depletion may improve the outcomes.<\/jats:p>","DOI":"10.1182\/hematology.2022000352","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:08Z","timestamp":1670602388000},"page":"534-538","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Allogeneic transplantation for advanced acute leukemia"],"prefix":"10.1182","volume":"2022","author":[{"given":"Daniel","family":"Weisdorf","sequence":"first","affiliation":[{"name":"University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"12","key":"2022120916094397600_hem2022000352C1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2022120916094397600_hem2022000352C2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.beha.2011.09.011","article-title":"Transplants for leukemia in relapse: when is the best time?","volume":"24","author":"Weisdorf","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"2022120916094397600_hem2022000352C3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2017.56","article-title":"How good are we at predicting the fate of someone with acute myeloid leukaemia?","volume":"31","author":"Estey","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2022120916094397600_hem2022000352C4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2022120916094397600_hem2022000352C5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjh.16355","article-title":"The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience","volume":"188","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"key":"2022120916094397600_hem2022000352C6","article-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides","author":"Auletta","year":"2021"},{"issue":"7","key":"2022120916094397600_hem2022000352C7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"2022120916094397600_hem2022000352C8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41409-021-01261-6","article-title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","volume":"56","author":"Percival","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2022120916094397600_hem2022000352C9","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2022120916094397600_hem2022000352C10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","article-title":"Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors","volume":"8","author":"Guru Murthy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"2022120916094397600_hem2022000352C11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2022120916094397600_hem2022000352C12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bmt.2017.171","article-title":"Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome\/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party","volume":"52","author":"Scheid","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2022120916094397600_hem2022000352C13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41409-022-01582-0","article-title":"Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study","volume":"57","author":"Lindholm","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"2022120916094397600_hem2022000352C14","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022120916094397600_hem2022000352C15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/hematology.2019000060","article-title":"MRD evaluation of AML in clinical practice: are we there yet?","volume":"2019","author":"Freeman","year":"2019","journal-title":"Hematology"},{"issue":"5","key":"2022120916094397600_hem2022000352C16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","article-title":"Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation","volume":"55","author":"Othus","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2022120916094397600_hem2022000352C17","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"2022120916094397600_hem2022000352C18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2022120916094397600_hem2022000352C19","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"2022120916094397600_hem2022000352C20","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2022120916094397600_hem2022000352C21","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2022120916094397600_hem2022000352C22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"39","key":"2022120916094397600_hem2022000352C23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/EDBK_238687","article-title":"How precision medicine is changing acute myeloid leukemia therapy","volume":"91","author":"Heuser","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"25","key":"2022120916094397600_hem2022000352C24","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2019-04-901181","article-title":"Message from the void: MRD analysis from ctDNA","volume":"133","author":"Heuser","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2022120916094397600_hem2022000352C25","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2022120916094397600_hem2022000352C26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022120916094397600_hem2022000352C27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022120916094397600_hem2022000352C28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2022120916094397600_hem2022000352C29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2022120916094397600_hem2022000352C30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","article-title":"Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: Particular activity against advanced hematologic malignancies","volume":"112","author":"Marks","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2022120916094397600_hem2022000352C31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/bmt.2010.181","article-title":"High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML","volume":"46","author":"O'Meara","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2022120916094397600_hem2022000352C32","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report [published correction appears in Blood Adv. 2021;5(13):2752]","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2022120916094397600_hem2022000352C33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.26000","article-title":"The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukemia: on behalf of the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"96","author":"Poiani","year":"2021","journal-title":"Am J Hematol"},{"issue":"23","key":"2022120916094397600_hem2022000352C34","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022120916094397600_hem2022000352C35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1182\/blood-2021-149962","article-title":"Prompt CR plus consolidation therapy yields improve survival after allogeneic transplantation for AML patients receiving myeloablative, but not reduced-intensity conditioning: a CIBMTR analysis","volume":"138","author":"Boyiadzis","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2022120916094397600_hem2022000352C36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"2022120916094397600_hem2022000352C37","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022120916094397600_hem2022000352C38","doi-asserted-by":"crossref","first-page":"100829","DOI":"10.1016\/j.blre.2021.100829","article-title":"AML and the art of remission maintenance","volume":"49","author":"de Lima","year":"2021","journal-title":"Blood Rev"},{"issue":"21","key":"2022120916094397600_hem2022000352C39","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients [published correction appears in Blood Adv. 2021;5(6):1755-1756]","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2022120916094397600_hem2022000352C40","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/10428194.2020.1789630","article-title":"Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"61","author":"Ali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2022120916094397600_hem2022000352C41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbmt.2013.11.017","article-title":"Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation","volume":"20","author":"Hourigan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2022120916094397600_hem2022000352C42","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/ajh.25983","article-title":"NK cell alloreactivity in acute myeloid leukemia in the post-transplant cyclophosphamide era","volume":"95","author":"Van Elssen","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/534\/2021688\/534weisdorf.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/534\/2021688\/534weisdorf.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:30Z","timestamp":1670602410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/534\/493542\/Allogeneic-transplantation-for-advanced-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000352","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}